Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
about
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation.Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.Translational research and application of basic biology to clinical trial development in GI cancers.Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
P2860
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Serum VEGF-A and CCL5 levels a ...... h metastatic colorectal cancer
@ast
Serum VEGF-A and CCL5 levels a ...... h metastatic colorectal cancer
@en
type
label
Serum VEGF-A and CCL5 levels a ...... h metastatic colorectal cancer
@ast
Serum VEGF-A and CCL5 levels a ...... h metastatic colorectal cancer
@en
prefLabel
Serum VEGF-A and CCL5 levels a ...... h metastatic colorectal cancer
@ast
Serum VEGF-A and CCL5 levels a ...... h metastatic colorectal cancer
@en
P2093
P2860
P356
P1433
P1476
Serum VEGF-A and CCL5 levels a ...... h metastatic colorectal cancer
@en
P2093
Eiji Shinozaki
Kensei Yamaguchi
Mitsukuni Suenaga
Naomi Kawata
Nobuyuki Mizunuma
Satoshi Matsusaka
Shingo Dan
Takeru Wakatsuki
Tetsuo Mashima
Toshiharu Yamaguchi
P2860
P304
34811-34823
P356
10.18632/ONCOTARGET.9187
P407
P577
2016-05-05T00:00:00Z